A The effects of DM with and without metformin for HCC risk after excluding 78 IFN failed patients who experienced retreatment with DAAs

Groups		BL	1Y	3Y	5Y	8Y	10Y	bCrude SHR (95% CI) P-value	b*Adjusted SHR (95% CI) P-value
DM	No. at risk	284	272	229	170	72	20		
metformin non-use	Cumulative Incidence (%)		2.5	12.0	16.7	27.1	28.0	1.53 (1.17-2.00)	1.50 (1.13-1.98)
								P=0.002	P=0.005
DM	No. at risk	326	326	320	292	189	93		
metformin use	Cumulative Incidence (%)		0	0.6	3.2	12.8	19.7	0.82 (0.63-1.07)	0.95 (0.73-1.25)
								P=0.134	P=0.729
Non-DM	No. at risk	2,091	2,029	1,853	1,420	683	261		
	Cumulative Incidence (%)		1.6	6.6	11.3	17.9	21.7	1	1

Supplementary Figure 3. The impact of DM with and without metformin (A) and HLP with and without statin (B) on the new-onset HCC among CHC patients who failed IFN therapy and did not subsequently receive DAAs treatment (n=2,701). (A) [a]After considering death as a competing risk, a Kaplan–Meier plot was constructed using Gray's cumulative incidence method. [b]All SHRs (95% CIs) and *P*-values were calculated using the Cox sub-distribution hazards method. *Adjusted for age, sex, LC, HCV GT1, HCV RNA, aspirin, and HLP/statin. DM, diabetes mellitus; HLP, hyperlipidemia; HCC, hepatocellular carcinoma; SHR, sub-distribution hazard ratio; LC, liver cirrhosis; GT, genotype. (B) [a]After considering death as a competing risk, a Kaplan–Meier plot was constructed using Gray's cumulative incidence method. [b]All SHRs (95% CIs) and *P*-values were calculated using the Cox sub-distribution hazards method. *Adjusted for age, sex, LC, HCV GT1, HCV RNA, aspirin, and DM/metformin. DM, diabetes mellitus; HLP, hyperlipidemia; HCC, hepatocellular carcinoma; SHR, sub-distribution hazard ratio; LC, liver cirrhosis; GT, genotype.

[a]Gray's *P*<0.001

HLP statin non-use

Non-HLP

HLP statin use

B The effects of HLP with and without statin for HCC risk after excluding 78 IFN failed patients who experienced retreatment with DAAs

Groups		BL	1Y	3Y	5Y	8Y	10Y	[b]Crude SHR (95% CI) P-value	[b]*Adjusted SHR (95% CI) P-value
HLP	No. at risk	101	98	90	59	32.0	7		
statin non-use	Cumulative Incidence (%)		2.0	6.9	10.6	12.1	14.8	0.75 (0.44-1.28) *P*=0.296	0.70 (0.41-1.18) *P*=0.181
HLP	No. at risk	485	485	474	417	236	108		
statin use	Cumulative Incidence (%)		0.2	0.8	3.7	9.2	11.7	0.41 (0.31-0.55) *P*<0.001	0.45 (0.33-0.60) *P*<0.001
Non-HLP	No. at risk	2,115	2,044	1,838	1,406	676	257		
	Cumulative Incidence (%)		1.8	7.7	12.5	20.7	25.5	1	1

Supplementary Figure 3. Continued